Two clinical studies published in the New England Journal of Medicine with an accompanying editorial suggest that the novel agent ibrutinib shows real potential as a safe, effective, targeted treatment for adults with chronic lymphocytic leukemia (CLL) and for patients with mantle cell lymphoma...
Behold the power of green veggies! A new study revealed that a compound found in cruciferous veggies, like broccoli, can not only prevent--but kill-- leukemia cells. Published in the journal PLoS ONE, researchers found that a specific compound in vegetables like broccoli--sulforaphane--caused...
A new drug used to treat patients with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute leukemia (Ph+ ALL) has just received approval from the U.S. Food and Drug Administration. The drug, Iclusig (ponatinib), was expected to be approved on March 27, 2013, but as there...
Leukemia patients who received infusions of their own T cells, after the cells had been genetically engineered to fight the patients' cancerous tumors, reacted to the therapy in a positive way, staying in full remission for over two years. The new therapy was developed by a group of scientists...
Researchers at Dana-Farber Cancer Institute have developed a novel method for determining how ready acute myeloid leukemia (AML) cells are to die, a discovery that may help cancer specialists to choose treatments option more effectively for their patients who have AML...
More...
Hundreds of mutations exist in leukemia cells at the time of diagnosis, but nearly all occur randomly as a part of normal aging and are not related to cancer, new research shows. Scientists at Washington University School of Medicine in St. Louis have found that even in healthy people, stem...
Many patients with acute myeloid leukemia (AML) share a mutation in a gene called IDH. A University of Colorado Cancer Center study published this week in the journal Leukemia & Lymphoma shows that this IDH mutation may be the first domino in a chain that leads to a more aggressive form of the...
Loss of a particular microRNA in chronic lymphocytic leukemia shuts down normal cell metabolism and turns up alternative mechanisms that enable cancer cells to produce the energy and build the molecules they need to proliferate and invade neighboring tissue. The findings come from a new study...
The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of elderly patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial. The phase I/II trial, co-led by researchers at the Ohio State University Comprehensive Cancer Center...
A study has identified microRNA-3151 as a new independent prognostic marker in certain patients with acute leukemia. The study involves patients with acute myeloid leukemia and normal-looking chromosomes(CN-AML). The study by researchers at the Ohio State University Comprehensive Cancer Center -...
A French study published Online First in The Lancet has revealed that fractionizing the dosage of the targeted anticancer drug gemtuzumab ozogamicin allows for safer delivery of the drug into patients between the ages of 50 to 70 years with acute myeloid leukemia (AML) and significantly improves...
An international group of researchers, including those from Moffitt Cancer Center in Tampa, Fla., have published a paper in the New England Journal of Medicine reviewing the results of a study that analyzed mutations in 18 genes of 398 patients who had acute myeloid leukemia (AML). They found...
Clinician-scientists in the Princess Margaret Cancer Program have found a promising approach to treating leukemia, using an old drug in a new way. The proof-of-concept research published today in Cancer Cell (10.1016/j.ccr.2011.10.015) describes how the Canadian team discovered that the...
Researchers have developed a new potential leukemia therapy that specifically targets cancerous cells, without attacking healthy cells. At present the majority of chemotherapy treatments attack both cancer cells and healthy cells, causing considerable adverse effects, such as depression...
Loyola University Chicago Stritch School of Medicine (SSOM) received a $100,000 grant to support research to treat an aggressive form of pediatric leukemia. The grant, which was funded by Hyundai's Hope on Wheels program, was presented to Loyola during a special ceremony with cancer patients and...
There are numerous specialized growth factors that are responsible for cells of different tissues of our body to divide and differentiate when needed. These hormone-like factors bind to matching receptors on the surface of their target cells and thus give order for the cell to divide. However, a...
In a cancer treatment breakthrough 20 years in the making, researchers from the University of Pennsylvania's Abramson Cancer Center and Perelman School of Medicine have shown sustained remissions of up to a year among a small group of advanced chronic lymphocytic leukemia (CLL) patients treated...
my boyfriends little brother is 6 and he is in remission from leukemia. i saw a sheet on the refrigerator that said that his blood counts were low. the normal white blood cell count is 4.5-6, and his was a 2.0. he was also low in red blood cells, lymphs, and a few other things. my boyfriend said...
New Clue In Leukemia Mystery: Researchers Identify "Poison" Employed By Deadly Enzyme
There is new hope for people with acute myelogenous leukemia (AML), a fast-growing cancer of the blood and bone marrow. Research led by Weill Cornell Medical College and published today in the online edition...
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that growth in the leukemia market will be driven mostly by chronic myelogenous leukemia (CML) therapies (Novartis's Gleevec and Tasigna and Bristol-Myers Squibb's Sprycel)...